PDS Biotechnology (PDSB) Projected to Post Earnings on Thursday

PDS Biotechnology (NASDAQ:PDSB) will likely be posting its Q3 2025 results before the market opens on Thursday, November 13th. Analysts expect PDS Biotechnology to post earnings of ($0.21) per share for the quarter. Individuals may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 13, 2025 at 8:30 AM ET.

PDS Biotechnology (NASDAQ:PDSB) last posted its quarterly earnings results on Wednesday, August 13th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.03. On average, analysts expect PDS Biotechnology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

PDS Biotechnology Trading Up 1.9%

PDSB stock opened at $0.91 on Thursday. PDS Biotechnology has a 1-year low of $0.85 and a 1-year high of $3.41. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.92 and a quick ratio of 2.92. The company has a market capitalization of $42.56 million, a price-to-earnings ratio of -0.98 and a beta of 1.11. The business has a 50 day simple moving average of $1.05 and a two-hundred day simple moving average of $1.23.

Institutional Trading of PDS Biotechnology

An institutional investor recently bought a new position in PDS Biotechnology stock. Marshall Wace LLP purchased a new stake in shares of PDS Biotechnology Corporation (NASDAQ:PDSB) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 68,454 shares of the company’s stock, valued at approximately $91,000. Marshall Wace LLP owned 0.15% of PDS Biotechnology as of its most recent filing with the SEC. Institutional investors and hedge funds own 26.84% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of PDS Biotechnology in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $10.00.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.